

Markus H. Meier

Before retiring from the Federal Trade Commission at the end of 2023, Markus spent 17 years as the Assistant Director in charge of the FTC's Health Care Division. In this capacity, he led an office of thirty-five lawyers and other professionals investigating and litigating antitrust cases involving pharmaceutical companies and health-care providers. Notable pharma cases Markus led include the *Actavis* "pay-for-deal" case, which resulted in a favorable decision by the Supreme Court; the *Cephalon* litigation, which resulted in a \$1.2 billion settlement on the eve of trial; and the *Vyera* trial, which resulted in a lifetime ban of "Pharma Bro" Martin Shkreli from working in the pharmaceutical industry.

From November 2015 to November 2017, Markus also served as the FTC's acting Deputy Director of the Bureau of Competition, including a stint as the acting Director. In this capacity, he oversaw more than 280 lawyers and other professionals investigating and litigating merger and non-merger cases across a range of industries. Markus joined the FTC in 1990.

In addition to working at the FTC, Markus has been in private practice, where he worked on antitrust litigation and represented clients before the FTC and Department of Justice. He also has served as a Special Assistant United States Attorney, prosecuting criminal cases. And he was a resident advisor to the Indonesian Competition Commission in Jakarta for six months in 2001.

Before joining the FTC, Markus served as an officer in the United States Army. He is a graduate of the George Mason School of Law, has a master's degree in public administration from Old Dominion University, and a bachelor's degree from the University of Virginia.